Bavarian Nordic will get an accelerated review of its chikungunya vaccine CHIKV VLP at the EMA, as it tries to chase down a lead held by rival Valneva.
GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, al
The UK government is reportedly considering a financial aid package to encourage AstraZeneca to invest in an expansion of its vaccines manufacturing facility in Speke, nea
Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines.
The Novo Nordisk Foundation (NNF) is funding a major new R&D initiative in the area of respiratory infections, with up to DKK 1.8 billion ($260 million) earmarked for
Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icos
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.